Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors
Sponsor: Huashan Hospital
Summary
This study will investigate the safety and preliminary diagnostic efficacy of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 in pancreatic cancer, breast cancer, head and neck cancer, lung cancers and other types of solid tumors. Then, this study will provide a new method for the noninvasive target-specific diagnosis of pancreatic cancer, breast cancer, head and neck cancer, lung cancers and other types of solid tumors. PET imaging of TROP-2 will be integrated to TROP-2-targeted therapies in some of the included patients. Therefore, PET imaging with \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 will help select patients for targeted therapy and monitor treatment responses after the treatment.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-12-01
Completion Date
2024-12-01
Last Updated
2024-06-18
Healthy Volunteers
No
Conditions
Interventions
[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4
The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
Locations (1)
Huashan Hospital
Shanghai, China